tru Independence’s Alnylam Pharmaceuticals ALNY Stock Holding History

tru Independence’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4	Closed	-$1	–	310
2020 Q4	$1	Buy	+4	New	+$534	﹤0.01%	656

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

tru Independence's ALNY Position: Q1 2021 in Review

tru Independence sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2021, closing a stake of 4 shares — an estimated $1 sold.

tru Independence first reported a position in ALNY in Q4 2020 and held it in 1 quarter. The position peaked at $1 in Q4 2020. 391 funds tracked by Wall St. Rank hold ALNY as of Q1 2021.

tru Independence reported no remaining Alnylam Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
tru Independence sold 4 Alnylam Pharmaceuticals shares in Q1 2021, an estimated $1.
tru Independence first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 1 quarter.
tru Independence's Alnylam Pharmaceuticals position peaked at $1 in Q4 2020.
391 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2021.

Based on tru Independence's 13F filing for Q1 2021, filed 20 May 2021.